News

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

“We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s Lab-to-Launch initiative,” said Mike Grisham, CEO of Virginia Catalyst. “Collaboration between our research universities and industry drives innovations that contribute to economic development in the Commonwealth.”

We encourage those of you with innovative ideas in life sciences to reach out to colleagues and other professionals to create a high-performing team. World-class research, entrepreneurial management, and capital can achieve great things together. You have several months to get a team together and submit an LOI by January 16. We award non-dilutive grants of $200k to $800k, plus we provide great contacts with other sources of capital and strategic partnerships.

Letters of Intent (LOI) must be received by January 16, 2026, at 5:00 PM Eastern Time. Projects that meet funding criteria will be invited to submit a full application by March 20, 2026. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists, and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to present their proposal in April, and awards will be announced in May 2026. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding, and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH, and philanthropic foundations. This webinar can be viewed, and the slides downloaded, on the home page of Virginia Catalyst at: https://www.virginiacatalyst.org/

Cumulatively, through the first 18 funding rounds, Virginia Catalyst has dedicated a total of over $38 million for 72 collaborative projects. Together, these projects have created over 450 new jobs and have attracted nearly $900 million of investment capital from venture capital, private equity, corporations, and government agencies including DARPA, NIH, and NSF, as well as through acquisitions.

Recent News

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza